To test whether anti-PCSK9 antibodies as a monotherapy have a direct impact on endotoxemia and to rule out any potential synergic effect of treatment combinations, we did not use antibiotics. The gene discussed is PCSK9; the disease is serum lipopolysaccharide activity.